Latest Development Pipeline News

Centuria Industrial REIT (ASX:CIP) reported a 20.5% jump in net profit to $160.4 million for FY26, underpinned by strong leasing activity, premium asset divestments, and advancing data centre initiatives.

CDL Investments New Zealand reported a modest profit decline for the first half of 2026, reflecting ongoing residential market challenges, while securing a $20 million credit facility to support future development.

Locality Planning Energy has consolidated its debt into a $7.2 million Westpac facility, lowering borrowing costs and freeing capital to back a $5.8 million development pipeline.

Li-FT Power Ltd. has secured a C$20 million bought deal public offering priced at C$2.90 per share, aimed at funding care and maintenance for the Renard option period and general working capital. The deal includes a 15% over-allotment option and anticipates participation from cornerstone investor Avenir Minerals.

Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.

Dexus has agreed to sell its half stake in 480 Queen Street, Brisbane, for $700 million, freeing capital to support higher-return projects and reduce gearing by about one percentage point.

RooLife Group (ASX:RLG) is expanding its renewable energy footprint by acquiring a battery storage and microgrid business and raising $1.06 million in a placement to fund growth and project delivery.

Locality Planning Energy (ASX:LPE) posted positive operating cash flow for FY26 and secured three residential development partnerships, while planning to refinance its debt facilities to boost capital efficiency.

Deterra Royalties reported a record A$61.8 million iron ore royalty revenue from Mining Area C in the June 2026 quarter, alongside significant progress at the Thacker Pass lithium project with US$1.21 billion drawn from a US Department of Energy loan.

Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.

Stanmore Resources bounced back from early-year weather disruptions with a 27% jump in ROM coal production in Q2 2026 and secured a refinancing deal that lowers debt costs and extends maturities, positioning the company for a robust second half.

Radiopharm Theranostics (ASX: RAD) has requested an immediate voluntary suspension of its shares pending a material capital raising announcement expected before markets open on 27 July 2026.